Mei Methawasin, MD, PhD, is a researcher focused on uncovering the pathological mechanisms underlying heart failure with preserved ejection fraction (HFpEF). Dr. Methawasin approaches HFpEF from the perspective of myofilaments, the downstream effectors that regulate the physiology of the cardiomyocytes and ultimately the mechanical function of the heart. Importantly, the properties of myofilaments can be altered rapidly (a time of minutes to days), making them attractive targets for therapeutic intervention. Her research explores whether targeting myofilaments could be an effective strategy to alleviate diastolic dysfunction in conditions like HFpEF, where upstream pathological signaling remains unresolved.